TLR4 activation leads to anti-EGFR therapy resistance in head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in head and neck squamous cell carcinoma (HNSCC), a target for therapy.
• Resistance to anti-EGFR therapy is a significant clinical challenge in HNSCC.
• Toll-like receptor 4 (TLR4) expression is elevated in a subset of HNSCC and linked to poor outcomes.

Purpose of the Study:

• To investigate the role of TLR4 in anti-EGFR therapy resistance in HNSCC.
• To elucidate the molecular mechanisms underlying the crosstalk between EGFR and TLR4 pathways.
• To evaluate TLR4 as a potential therapeutic target and biomarker in HNSCC.

Main Methods:

• Analysis of TLR4 expression in HNSCC biopsies and cell lines.
• Assessment of TLR4 activation effects on HNSCC cell proliferation, migration, and invasion.
• Investigation of downstream signaling pathways (NF-κB, MAPK) and inflammatory molecules (TNF-α, COX2).
• Mechanistic studies involving EGFR inhibition, Src, Cbl-b, and MyD88.
• Evaluation of cetuximab and gefitinib resistance in TLR4/MyD88 overexpressing cells in vitro and in vivo.

Main Results:

• TLR4 activation counteracted cetuximab-induced inhibition of HNSCC cell proliferation, migration, and invasion.
• Cetuximab treatment potentiated LPS-induced TLR4 signaling, increasing NF-κB and MAPK pathway activation.
• EGFR inhibition by cetuximab led to Src/Cbl-b pathway alterations, enhancing TLR4 signaling via MyD88.
• Overexpression of TLR4 or MyD88 conferred resistance to anti-EGFR drugs (cetuximab, gefitinib) in HNSCC cells.
• TLR4 overexpression correlated with worse prognosis in EGFR-overexpressing HNSCC patients.

Conclusions:

• A novel crosstalk mechanism between EGFR and TLR4 pathways in HNSCC was identified.
• TLR4 activation promotes resistance to anti-EGFR therapy by modulating downstream signaling and inflammation.
• TLR4 represents a promising biomarker and therapeutic target for overcoming anti-EGFR resistance in HNSCC.